Form 4: Tandem Diabetes CSO Reports RSU Vesting & Tax Withholding

Tandem Diabetes Care's Chief Strategy Officer, Elizabeth Gasser, reported the vesting of restricted stock units and associated tax withholdings.

Summary

• Elizabeth Gasser, EVP, Chief Strategy Officer for Tandem Diabetes Care Inc. (TNDM), reported transactions on August 15, 2025.
• Acquired 1,503 shares of common stock upon the vesting of restricted stock units (RSUs) at an exercise price of $0.00.
• Disposed of 805 shares at a price of $10.82 to satisfy tax withholding requirements related to the RSU vesting.
• Acquired an additional 1,097 shares of common stock from a separate RSU vesting event at an exercise price of $0.00.
• Disposed of 588 shares at a price of $10.82 for tax withholding purposes related to the second RSU vesting.
• Following these reported transactions, Gasser directly owns 1,207 shares of common stock.
• Gasser also indirectly owns 22,949 shares of common stock through The Gasser Family Trust dated September 1, 2011.
• Remaining unvested RSUs include 4,509 from an award granted on May 25, 2023, and 7,677 from an award granted on May 23, 2024, both under the 2023 Long-Term Incentive Plan.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 disclosing executive compensation events (RSU vesting and tax withholding), which are neutral in nature and do not indicate positive or negative operational or financial performance.

Positives

• The vesting of restricted stock units indicates continued long-term incentive alignment between the executive and shareholders.
• The acquisition of shares at a $0.00 exercise price represents an increase in the executive's direct beneficial ownership of company stock.

Negatives

• Shares were disposed of solely to cover tax withholding requirements on RSU vesting, which is a routine and non-discretionary event, not a sale by the executive.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of executive stock transactions, common across all publicly traded companies, and does not reflect specific industry trends in the diabetes care sector. It primarily details compensation-related events for a key executive.

Comparison to Industry Standards

• The reported transactions, specifically the vesting of Restricted Stock Units (RSUs) and subsequent share withholding for tax purposes, are standard practices for executive compensation in publicly traded companies across various industries.
• This aligns with common long-term incentive plans designed to align executive interests with shareholder value, similar to practices at companies like Insulet Corporation (PODD) or Dexcom, Inc. (DXCM) within the diabetes technology space, or broader healthcare companies.

Related Party Transactions

• The disposition of shares for tax withholding purposes is a transaction with the issuer (Tandem Diabetes Care, Inc.) to satisfy statutory obligations related to executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation events, aligning executive incentives with company performance.
• Employees: No direct impact indicated beyond the executive involved.
• Customers/Suppliers/Creditors: No direct impact indicated.

Next Steps

• The remaining shares from the May 25, 2023 RSU award are scheduled to vest in eight equal quarterly installments after May 15, 2024.
• The remaining shares from the May 23, 2024 RSU award are scheduled to vest in eight equal quarterly installments after May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of Restricted Stock Units (RSUs) and the associated tax withholding. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal any significant positive or negative developments for the company's stock price. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Elizabeth Gasser, Stock Ownership, Tax Withholding